386 related articles for article (PubMed ID: 19746839)
1. Topical administration of cyclosporin A in a solid lipid nanoparticle formulation.
Kim ST; Jang DJ; Kim JH; Park JY; Lim JS; Lee SY; Lee KM; Lim SJ; Kim CK
Pharmazie; 2009 Aug; 64(8):510-4. PubMed ID: 19746839
[TBL] [Abstract][Full Text] [Related]
2. Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems.
Sandri G; Bonferoni MC; Gökçe EH; Ferrari F; Rossi S; Patrini M; Caramella C
J Microencapsul; 2010; 27(8):735-46. PubMed ID: 21034366
[TBL] [Abstract][Full Text] [Related]
3. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery.
Liu J; Hu W; Chen H; Ni Q; Xu H; Yang X
Int J Pharm; 2007 Jan; 328(2):191-5. PubMed ID: 16978810
[TBL] [Abstract][Full Text] [Related]
4. Solid lipid nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: in-vitro characterization, ex-vivo and in-vivo studies.
Sanna V; Gavini E; Cossu M; Rassu G; Giunchedi P
J Pharm Pharmacol; 2007 Aug; 59(8):1057-64. PubMed ID: 17725847
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity.
Gokce EH; Sandri G; Bonferoni MC; Rossi S; Ferrari F; Güneri T; Caramella C
Int J Pharm; 2008 Nov; 364(1):76-86. PubMed ID: 18725276
[TBL] [Abstract][Full Text] [Related]
6. A novel preparation of solid lipid nanoparticles with cyclosporin A for prolonged drug release.
Hu FQ; Wu MZh; Yuan H; Zhang HH
Pharmazie; 2004 Sep; 59(9):683-5. PubMed ID: 15497749
[TBL] [Abstract][Full Text] [Related]
7. Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterization.
Attama AA; Schicke BC; Paepenmüller T; Müller-Goymann CC
Eur J Pharm Biopharm; 2007 Aug; 67(1):48-57. PubMed ID: 17276663
[TBL] [Abstract][Full Text] [Related]
8. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery.
Shah KA; Date AA; Joshi MD; Patravale VB
Int J Pharm; 2007 Dec; 345(1-2):163-71. PubMed ID: 17644288
[TBL] [Abstract][Full Text] [Related]
9. Preparation of an alternative freeze-dried pH-sensitive cyclosporine A loaded nanoparticles formulation and its pharmacokinetic profile in rats.
Yang ZQ; Xu J; Pan P; Zhang XN
Pharmazie; 2009 Jan; 64(1):26-31. PubMed ID: 19216227
[TBL] [Abstract][Full Text] [Related]
10. Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy.
Lombardi Borgia S; Regehly M; Sivaramakrishnan R; Mehnert W; Korting HC; Danker K; Röder B; Kramer KD; Schäfer-Korting M
J Control Release; 2005 Dec; 110(1):151-63. PubMed ID: 16297487
[TBL] [Abstract][Full Text] [Related]
11. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation.
Puglia C; Blasi P; Rizza L; Schoubben A; Bonina F; Rossi C; Ricci M
Int J Pharm; 2008 Jun; 357(1-2):295-304. PubMed ID: 18343059
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporine a-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes.
Gökçe EH; Sandri G; Eğrilmez S; Bonferoni MC; Güneri T; Caramella C
Curr Eye Res; 2009 Nov; 34(11):996-1003. PubMed ID: 19958116
[TBL] [Abstract][Full Text] [Related]
13. Halobetasol propionate-loaded solid lipid nanoparticles (SLN) for skin targeting by topical delivery.
Bikkad ML; Nathani AH; Mandlik SK; Shrotriya SN; Ranpise NS
J Liposome Res; 2014 Jun; 24(2):113-23. PubMed ID: 24131382
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery.
Başaran E; Demirel M; Sirmagül B; Yazan Y
J Microencapsul; 2010; 27(1):37-47. PubMed ID: 19545226
[TBL] [Abstract][Full Text] [Related]
15. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
Müller RH; Runge S; Ravelli V; Mehnert W; Thünemann AF; Souto EB
Int J Pharm; 2006 Jul; 317(1):82-9. PubMed ID: 16580159
[TBL] [Abstract][Full Text] [Related]
16. Topical application of liposomal cobalamin hydrogel for atopic dermatitis therapy.
Jung SH; Cho YS; Jun SS; Koo JS; Cheon HG; Shin BC
Pharmazie; 2011 Jun; 66(6):430-5. PubMed ID: 21699082
[TBL] [Abstract][Full Text] [Related]
17. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC).
Fang JY; Fang CL; Liu CH; Su YH
Eur J Pharm Biopharm; 2008 Oct; 70(2):633-40. PubMed ID: 18577447
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation.
Müller RH; Runge SA; Ravelli V; Thünemann AF; Mehnert W; Souto EB
Eur J Pharm Biopharm; 2008 Mar; 68(3):535-44. PubMed ID: 17804210
[TBL] [Abstract][Full Text] [Related]
19. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery.
Souto EB; Wissing SA; Barbosa CM; Müller RH
Int J Pharm; 2004 Jun; 278(1):71-7. PubMed ID: 15158950
[TBL] [Abstract][Full Text] [Related]
20. RU 58841-myristate--prodrug development for topical treatment of acne and androgenetic alopecia.
Münster U; Nakamura C; Haberland A; Jores K; Mehnert W; Rummel S; Schaller M; Korting HC; Zouboulis ChC; Blume-Peytavi U; Schäfer-Korting M
Pharmazie; 2005 Jan; 60(1):8-12. PubMed ID: 15700772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
